Effects of Liraglutide on GLP-1, GIP and glucagon concentrations in persons with type 2 diabetes with multiple daily insulin injections during a 24-week period

被引：0
|
作者：
Koci, M. [1 ]
Jansson, P. -A. [2 ]
Fatulla, P. [2 ]
Bergqvist, K. [3 ]
Ahmadi, S. Seyed [2 ]
Imberg, H. [2 ]
Hirsch, I. [4 ]
Mellander, O. [5 ]
Lind, M. [2 ]
机构：
[1] Sahlgrens Univ Hosp, Dept Endocrinol & Diabet, Gothenburg, Sweden
[2] Gothenburg Univ, Dept Mol & Clini cal Med, Gothenburg, Sweden
[3] Gothenburg Univ, Dept Infect Dis, Gothenburg, Sweden
[4] UW Med Diabet Inst, Div Metab Endocrinol & Nutr, Seattle, WA USA
[5] Lund Univ, Dept Clin Sci Malmo, Malmo, Sweden
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
83
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [31] Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections
    Sheyda Sofizadeh
    Henrik Imberg
    Arndís F. Ólafsdóttir
    Magnus Ekelund
    Sofia Dahlqvist
    Irl Hirsch
    Karin Filipsson
    Bo Ahrén
    Stefan Sjöberg
    Jaako Tuomilehto
    Marcus Lind
    Diabetes Therapy, 2019, 10 : 2115 - 2130
  • [32] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on lipid profiling in patients with type 2 diabetes
    Ruotolo, G.
    Roth, K. D.
    Milligan, P. L.
    Lin, Y.
    Wilson, J. M.
    Pirro, V
    Duffin, K. L.
    Haupt, A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3056 - 3056
  • [33] Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes - A randomized, parallel-group, 24-week study
    Raskin, P
    Bode, BW
    Marks, JB
    Hirsch, IB
    Weinstein, RL
    McGill, JB
    Peterson, GE
    Mudaliar, SR
    Reinhardt, RR
    DIABETES CARE, 2003, 26 (09) : 2598 - 2603
  • [34] Effects of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, on metabolic profile in patients with type 2 diabetes
    Pirro, V.
    Willency, J. A.
    Wilson, J. M.
    Roth, K. D.
    Lin, Y.
    Collins, K. A. L.
    Ruotolo, G.
    Haupt, A.
    Newgard, C. B.
    Duffin, K. L.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S73 - S73
  • [35] Head to head comparison of glucagon-like peptide 1 (GLP-1) agonists and insulin in patients with Type 2 diabetes
    Siddiqi, Al
    Nambi, S.
    DIABETIC MEDICINE, 2013, 30 : 163 - 163
  • [36] Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes
    Ostergaard, Lauge
    Frandsen, Christian Seerup
    Dejgaard, Thomas Fremming
    Madsbad, Sten
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (06) : 621 - 632
  • [37] Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes
    Manell, Hannes
    Staaf, Johan
    Manukyan, Levon
    Kristinsson, Hjalti
    Cen, Jing
    Stenlid, Rasmus
    Ciba, Iris
    Forslund, Anders
    Bergsten, Peter
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (03): : 1181 - 1189
  • [38] Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial
    Ando, Yasuyo
    Shigiyama, Fumika
    Hirose, Takahisa
    Kumashiro, Naoki
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (10) : 1816 - 1826
  • [39] The once-daily human GLP-1 analog-liraglutide reduces systolic blood pressure in patients with type 2 diabetes
    Colagiuri, Steven
    Frid, Anders
    Zdravkovic, Milan
    Le-Thi, Tu Duyen
    Vaag, Allan
    DIABETES, 2008, 57 : A164 - A165
  • [40] Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes
    Thomas, Melissa K.
    Nikooienejad, Amir
    Bray, Ross
    Cui, Xuewei
    Wilson, Jonathan
    Duffin, Kevin
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2021, 106 (02): : 388 - 396
12345